Health Law & Business News

Celgene’s First Therapy For Rare Form of Anemia Approved by FDA

Nov. 8, 2019, 9:46 PM

The FDA cleared the first therapy for adult anemic patients with a rare inherited blood disorder, the agency said Nov. 8.

Reblozyl, made by Celgene Corp., helps patients suffering from the rare anemia who typically require regular red blood cell transfusions, according to the Food and Drug Administration.

Beta thalassemia, also known as Cooley’s anemia, reduces hemoglobin production, which helps red blood cells carry oxygen throughout the body. This can lead to a lack of oxygen in various body parts and blood as well as pale skin, weakness, fatigue, and more serious complications, the agency said. These patients can also...

To read the full article log in. To learn more about a subscription click here.